Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis

• Published in: Journal of the European Academy of Dermatology and Venereology 2020-08, Vol.34 (S6), p.10-16
• Main Authors: Thouvenin, M.D., Dalmon, S., Theunis, J., Lauze, C., Coubetergues, H., Mengeaud, V., Calvet, B.
• Format: Article
• Language: English
• Subjects: Adult; Humans; Pentacyclic Triterpenes - therapeutic use; Psoriasis - drug therapy; Quality of Life; Treatment Outcome; Triterpenes - therapeutic use
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.16691

Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone or in association with topical or systemic drug treatments or phototherapy, and its efficacy when used alone. Methods Adults with body plaque psoriasis applied the product over the whole body once a day for 4 weeks (balm used alone in 41 patients and with ongoing treatment in 50 patients). At D1, D8 (‘balm alone’ study) or D15 (‘balm in association’ study) and D29, the dermatologist rated physical and functional signs and assessed pruritus and body global lesion score (evaluating erythema, induration/thickness, scaling and dryness) in the ‘balm alone’ study. Results No reaction related to the product was reported, and the tolerance was deemed excellent. In the ‘balm alone’ study, mean pruritus intensity score significantly decreased at D8 (−39%, P